Drug Patents Expiring in 2023

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Mar, 2023

(5 months from now)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Mar, 2023

(5 months from now)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole Aug, 2023

(9 months from now)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole Aug, 2023

(9 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

4. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138229 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

US8314156 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

US7923536 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of breast cancer; treatment of pancreatic cancer; treatment of lung cancer; Treatment of lung cancer; treatment of pancreatic cancer; Treatment of pancreatic cancer; treatment of lung cancer; treatment of breast cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

5. Drug name - ACTONEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 APIL Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7718634 APIL Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7718634

(Pediatric)

APIL Method of treatment using bisphosphonic acid Nov, 2023

(1 year, 1 month from now)

US7192938

(Pediatric)

APIL Method of treatment using bisphosphonic acid Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
35MG TABLET;ORAL Prescription
75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET;ORAL Discontinued
150MG TABLET;ORAL Prescription

6. Drug name - ACTOPLUS MET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 15MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
1GM;EQ 30MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

7. Drug name - ADDYI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin May, 2023

(7 months from now)

US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin May, 2023

(7 months from now)

Drugs and Companies using FLIBANSERIN ingredient

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

8. Drug name - ADVAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXO GRP LTD Actuation indicator for a dispensing device Jun, 2023

(8 months from now)

US7832351

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device Dec, 2023

(1 year, 2 months from now)

More Information on Dosage
Strength Dosage Availability
0.045MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription
0.115MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription
0.23MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription

9. Drug name - AFINITOR DISPERZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide Mar, 2023

(5 months from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET, FOR SUSPENSION;ORAL Prescription
3MG TABLET, FOR SUSPENSION;ORAL Prescription
5MG TABLET, FOR SUSPENSION;ORAL Prescription

10. Drug name - AGGRASTAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660 MEDICURE Method for inhibiting platelet aggregation May, 2023

(6 months from now)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

11. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler May, 2023

(6 months from now)

US7540282

(Pediatric)

TEVA PHARM Reservoir pressure system for medicament inhaler Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

12. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription

13. Drug name - ALPHAGAN P

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components Sep, 2023

(10 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

14. Drug name - AMRIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375410 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7820203 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7544372 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US8877245 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US9399025 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7829121 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

US7790199 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Treatment: Relief of muscle spasm

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
30MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

15. Drug name - AMTURNIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic May, 2023

(7 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE;EQ 5MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 5MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 5MG BASE;25MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 10MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 10MG BASE;25MG TABLET;ORAL Discontinued

16. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

17. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler May, 2023

(6 months from now)

US7540282

(Pediatric)

TEVA PHARM Reservoir pressure system for medicament inhaler Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

18. Drug name - AXIRON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784878 ELI LILLY AND CO Transdermal delivery rate control using amorphous pharmaceutical compositions Jul, 2023

(9 months from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of transdermally delivering testosterone

Dosage: SOLUTION, METERED;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
30MG/1.5ML ACTUATION SOLUTION, METERED;TRANSDERMAL Discontinued

19. Drug name - BANZEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic May, 2023

(7 months from now)

Drugs and Companies using RUFINAMIDE ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;ORAL Prescription

20. Drug name - BEPREVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877168 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations Jul, 2023

(9 months from now)

Drugs and Companies using BEPOTASTINE BESILATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1.5% SOLUTION/DROPS;OPHTHALMIC Prescription

21. Drug name - BINOSTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964212 ASCEND THERAPS US Effervescent compositions comprising phosphonates and methods related thereto
Mar, 2023

(4 months from now)

US7488496 ASCEND THERAPS US Effervescent compositions comprising bisphosphonates and methods related thereto
Aug, 2023

(10 months from now)

EP2277503B1 ASCEND THERAPS US Effervescent Compositions Comprising Bisphosphonates
Mar, 2023

(4 months from now)

EP1490024A1 ASCEND THERAPS US Effervescent Compositions Comprising Alendronate
Mar, 2023

(4 months from now)

EP2277503A1 ASCEND THERAPS US Effervescent Compositions Comprising Bisphosphonates
Mar, 2023

(4 months from now)

EP1490024B1 ASCEND THERAPS US Effervescent Compositions Comprising Alendronate
Mar, 2023

(4 months from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 70MG BASE TABLET, EFFERVESCENT;ORAL Prescription

22. Drug name - BONIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7718634 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

US7410957 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid May, 2023

(6 months from now)

Drugs and Companies using IBANDRONATE SODIUM ingredient

Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET;ORAL Discontinued
EQ 150MG BASE TABLET;ORAL Discontinued

23. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

24. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Apr, 2023

(6 months from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

25. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Apr, 2023

(6 months from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

26. Drug name - CABENUVA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

27. Drug name - CHANTIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Feb, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

28. Drug name - CHLORAPREP ONE-STEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241065 BECTON DICKINSON CO Applicator for coloring antiseptic Mar, 2023

(5 months from now)

US6729786 BECTON DICKINSON CO Liquid applicator for coloring a liquid Mar, 2023

(5 months from now)

US7182536 BECTON DICKINSON CO Antiseptic applicator with mechanism for fracturing multiple ampoules Dec, 2023

(1 year, 2 months from now)

More Information on Dosage
Strength Dosage Availability
2%;70% (3ML) SPONGE;TOPICAL Over the counter
2%;70% (10.5ML) SPONGE;TOPICAL Over the counter
2%;70% (26ML) SPONGE;TOPICAL Over the counter
2%;70% (1ML) SPONGE;TOPICAL Over the counter
2%;70% (1.5ML) SPONGE;TOPICAL Over the counter

29. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7595021 SAGE PRODS Method of providing alcohol-free disinfection May, 2023

(7 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: For the preparation of skin prior to surgery; helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% CLOTH;TOPICAL Over the counter

30. Drug name - CLINDESSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899890 PADAGIS US Bioadhesive drug delivery system Apr, 2023

(6 months from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Treatment: Method of treating bacterial vaginosis

Dosage: CREAM;VAGINAL

More Information on Dosage
Strength Dosage Availability
EQ 2% BASE CREAM;VAGINAL Prescription

31. Drug name - COMBIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7323463 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
0.2%;EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

32. Drug name - COMPLERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;300MG TABLET;ORAL Prescription

33. Drug name - COREG CR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7268156 WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Jun, 2023

(8 months from now)

CN101898995B WOODWARD Carvedilol Phosphate Salts And/Or Solvates Thereof, Correspondinq Compositions, And/Or Methods Of Treatment
Jun, 2023

(8 months from now)

CN101898995A WOODWARD Carvedilol Phosphate Salts And/Or Solvates Thereof, Corresponding Compositions, And/Or Methods Of Treatment
Jun, 2023

(8 months from now)

IN200404035P1 WOODWARD Carvedilol Phosphate Salts And/Or Solvates Thereof,Corresponding Compositions, And/Or Methods Of Treatment
Jun, 2023

(8 months from now)

IN233599B WOODWARD Crystalline Carvedilol Dihydrogen Phosphate Hemihydrate And Pharmaceutical Composition Comprising The Same
Jun, 2023

(8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7268156

(Pediatric)

WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

34. Drug name - CUVPOSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7638552 MERZ PHARMS Method for increasing the bioavailability of glycopyrrolate Aug, 2023

(10 months from now)

US7816396 MERZ PHARMS Method for increasing the bioavailability of glycopyrrolate Aug, 2023

(10 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: Reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/5ML SOLUTION;ORAL Prescription

35. Drug name - CYCLOSET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8137992 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Jul, 2023

(9 months from now)

US8137993 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Jul, 2023

(9 months from now)

US8137994 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Jul, 2023

(9 months from now)

US7888310 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy Jul, 2023

(9 months from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Treatment: Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.8MG BASE TABLET;ORAL Prescription

36. Drug name - DALIRESP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Feb, 2023

(4 months from now)

US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient Feb, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
250MCG TABLET;ORAL Prescription
500MCG TABLET;ORAL Prescription

37. Drug name - DALVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections Nov, 2023

(1 year, 1 month from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections Nov, 2023

(1 year, 1 month from now)

US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration Nov, 2023

(1 year, 1 month from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/VIAL POWDER;INTRAVENOUS Prescription

38. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(9 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 9 days from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 9 days from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); to maintain healing of ee and relief of heartburn; for healing of all grades of erosive esophagitis (ee)

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

39. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(9 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 9 days from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

40. Drug name - DEXYCU KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6960346 EYEPOINT PHARMS Vehicles for delivery of biologically active substances Jul, 2023

(8 months from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage
Strength Dosage Availability
9% SUSPENSION;INTRAOCULAR Prescription

41. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703820 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US7834060 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US7838558 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US7868044 GALDERMA LABS LP Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid Mar, 2023

(5 months from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3% GEL;TOPICAL Prescription

42. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(9 months from now)

CN1688707A CUBIST PHARMS LLC Preparation Of Table Hook
Jul, 2023

(9 months from now)

CN100519757C CUBIST PHARMS LLC Preparation Of Tiacumicins
Jul, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

43. Drug name - DOPTELET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765764 AKARX INC 2-acylaminothiazole derivative or salt thereof Jan, 2023

(3 months from now)

US8338429 AKARX INC 2-acylaminothiazole derivative or salt thereof Jun, 2023

(8 months from now)

Drugs and Companies using AVATROMBOPAG MALEATE ingredient

Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

44. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(6 months from now)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(11 months from now)

EP1441735A1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1441735B1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

45. Drug name - DYMISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2023

(10 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Treatment: Treatment of seasonal allergic rhinitis; Treatment of seasonal allergic rhinitis; treatment of allergic rhinitis, including seasonal allergic rhinitis; allergic rhinitis; treatment of symptoms of seasonal allergic rhinitis; relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY;0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

46. Drug name - EDURANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7638522 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription

47. Drug name - ELIGARD KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8470359 TOLMAR THERAP Sustained release polymer
Oct, 2023

(1 year, 9 days from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Treatment: NA

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
45MG POWDER;SUBCUTANEOUS Prescription

48. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404744 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2023

(3 months from now)

US8796331 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2023

(3 months from now)

US8796331

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2023

(9 months from now)

US8404744

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2023

(9 months from now)

US7468390 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: Treatment of heart failure

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

49. Drug name - EPIDUO FORTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8729127 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US9387187 GALDERMA LABS Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US8703820 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US9381179 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3%;2.5% GEL;TOPICAL Prescription

50. Drug name - EXFORGE HCT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same May, 2023

(7 months from now)

US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents May, 2023

(7 months from now)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE;12.5MG;160MG TABLET;ORAL Prescription
EQ 5MG BASE;25MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;12.5MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;25MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;25MG;320MG TABLET;ORAL Prescription

51. Drug name - FENSOLVI KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(1 year, 9 days from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Treatment: NA

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
45MG POWDER;SUBCUTANEOUS Prescription

52. Drug name - FERAHEME

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6599498 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Jun, 2023

(8 months from now)

Drugs and Companies using FERUMOXYTOL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

53. Drug name - FINACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof Oct, 2023

(1 year, 18 days from now)

US8900554 LEO PHARMA AS Foamable composition and uses thereof Oct, 2023

(1 year, 18 days from now)

US8722021 LEO PHARMA AS Foamable carriers Oct, 2023

(1 year, 18 days from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% AEROSOL, FOAM;TOPICAL Prescription

54. Drug name - FLOVENT HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXO GRP LTD Actuation indicator for a dispensing device Jun, 2023

(8 months from now)

US7832351

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.044MG/INH AEROSOL, METERED;INHALATION Prescription
0.11MG/INH AEROSOL, METERED;INHALATION Prescription
0.22MG/INH AEROSOL, METERED;INHALATION Prescription

55. Drug name - FOTIVDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2023

(6 months from now)

US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2023

(1 year, 1 month from now)

EP1559715B1 AVEO PHARMS N-{2-Chloro-4-[(6,7-Dimethoxy-4-Quinolyl)Oxy]Phenyl}-N'-(5-Methyl-3-Isoxazolyl)Urea Salt In Crystalline Form
Oct, 2023

(1 year, 15 days from now)

EP1559715A1 AVEO PHARMS N-{2-Chloro-4-[(6,7-Dimethoxy-4-Quinolyl)Oxy]Phenyl}-N'-(5-Methyl-3-Isoxazolyl)Urea Salt In Crystalline Form
Oct, 2023

(1 year, 15 days from now)

EP1559715A4 AVEO PHARMS N-¬2-Chloro-4-(6,7-Dimethoxy-4-Quinolyl)OxyPhenyl-N'-(5-Methyl-3-Isoxazolyl)Urea Salt In Crystalline Form
Oct, 2023

(1 year, 15 days from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.89MG BASE CAPSULE;ORAL Prescription
EQ 1.34MG BASE CAPSULE;ORAL Prescription

56. Drug name - GATTEX KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056886

(Pediatric)

NPS PHARMS INC GLP-2 formulations Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
5MG/VIAL POWDER;SUBCUTANEOUS Prescription

57. Drug name - GLUMETZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323692 SANTARUS INC Controlled release dosage forms Mar, 2023

(5 months from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET, EXTENDED RELEASE;ORAL Prescription
500MG TABLET, EXTENDED RELEASE;ORAL Prescription

58. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

59. Drug name - HALAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(9 months from now)

Drugs and Companies using ERIBULIN MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1MG/2ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription

60. Drug name - HYSINGLA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
120MG TABLET, EXTENDED RELEASE;ORAL Prescription

61. Drug name - IBRANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

CN101001857A PFIZER 2-(Pyridine-2-Yl Amido)-Pyridino[2,3-D]Pyrimidine-7-Ketone
Jan, 2023

(3 months from now)

CN101001857B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN102295643B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101906104A PFIZER 2-(Pyrid-2-Ylamino)-Pyridino[2,3-D] Pyrimidine-7-One
Jan, 2023

(3 months from now)

CN101906104B PFIZER 2-(Pyridin-2-Yl Amino)-Pyrido [2, 3-D] Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN102295643A PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

IN200401733P1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

IN218291B PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124B1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124A1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D]Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones Jan, 2023

(3 months from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
125MG TABLET;ORAL Prescription

62. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155699 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

US8586093 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

US8404276 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

63. Drug name - INJECTAFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(1 year, 14 days from now)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(1 year, 14 days from now)

CN100480275C AM REGENT Water Soluble Iron Carbohydrate Complex, Its Preparation And Medicine Containing The Same
Oct, 2023

(1 year, 14 days from now)

CN1705682A AM REGENT Water Soluble Iron Carbohydrate Complex, Its Preparation And Medicine Containing The Same
Oct, 2023

(1 year, 14 days from now)

IN221536B AM REGENT Water Soluble Iron Carbohydrate Comples And A Process For Producing Water Soluble Iron Carboyydrate Complex
Oct, 2023

(1 year, 14 days from now)

IN200500947P2 AM REGENT Water Soluble Iron Carbohydrate Comples And A Process For Producing Water Soluble Iron Carboyydrate Comoplex
Oct, 2023

(1 year, 14 days from now)

EP2287204A1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 14 days from now)

EP2287204B1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 14 days from now)

EP1554315B1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 14 days from now)

EP1554315A1 AM REGENT Water-Soluble Iron-Carbohydrate Complexes, Production Thereof, And Medicaments Containing Said Complexes
Oct, 2023

(1 year, 14 days from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM IRON/20ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
750MG IRON/15ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
100MG IRON/2ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
500MG IRON/10ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

64. Drug name - INTUNIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6811794

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles Jan, 2023

(2 months from now)

Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 3MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

65. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(11 months from now)

EP1441735A1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1441735B1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

66. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

67. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

68. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

69. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

70. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

71. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

72. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

73. Drug name - KENGREAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6130208 CHIESI Formulation containing a nucleotide analogue Jun, 2023

(8 months from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

74. Drug name - KOMBIGLYZE XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

75. Drug name - KOSELUGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(5 months from now)

CN101633644B ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN100519539C ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645B ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682A ASTRAZENECA N3 Alkylated Benzoimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682B ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN1652776A ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645A ASTRAZENECA N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

CN101633644A ASTRAZENECA N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

IN200403046P1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

IN248684B ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2130537B1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810B1 ASTRAZENECA N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130536B1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2130536A1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102B1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810A1 ASTRAZENECA N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130537A1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102A1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A4 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932B1 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 25MG BASE CAPSULE;ORAL Prescription

76. Drug name - KYLEENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
19.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

77. Drug name - KYNAMRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(5 months from now)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(10 months from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
200MG/ML (200MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

78. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8663687 SUNOVION PHARMS INC Film compositions for delivery of actives Feb, 2023

(3 months from now)

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

79. Drug name - LAMICTAL XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547 GLAXOSMITHKLINE LLC Oral dosage form for controlled drug release Sep, 2023

(11 months from now)

Drugs and Companies using LAMOTRIGINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
200MG TABLET, EXTENDED RELEASE;ORAL Prescription
250MG TABLET, EXTENDED RELEASE;ORAL Prescription
300MG TABLET, EXTENDED RELEASE;ORAL Prescription

80. Drug name - LATISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8986715 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8263054 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8632760 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Method of increasing hair growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of increasing eyelash growth; Method of increasing growth of hair including eyelashes

Dosage: SOLUTION/DROPS;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.03% SOLUTION/DROPS;TOPICAL Prescription

81. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(4 months from now)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(1 year, 29 days from now)

EP1423404A2 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404A4 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404B1 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2278004A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157B1 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2902406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2287306B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A4 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP3354656B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2287305B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2902406A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128B1 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A2 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP3354656A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2278004B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A2 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A4 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1560840A2 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1562971A2 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1560840A4 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP2957568B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1560840B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP2957568A1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1562971A4 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1562971B1 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation Nov, 2023

(1 year, 29 days from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

82. Drug name - LEVITRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841446 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate Jul, 2023

(8 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Discontinued
EQ 5MG BASE TABLET;ORAL Discontinued
EQ 10MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Discontinued

83. Drug name - LEVOXYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7101569 KING PHARMS Methods of administering levothyroxine pharmaceutical compositions Oct, 2023

(11 months from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: Method of use of administering levothyroxine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.3MG TABLET;ORAL Discontinued

84. Drug name - LEXAPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram Feb, 2023

(4 months from now)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram Feb, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription

85. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511581 SUNOVION RESP Fluid droplet production apparatus and method Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

86. Drug name - LOSEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.02MG,0.1MG;0.01MG,N/A TABLET;ORAL Prescription

87. Drug name - MEKTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(5 months from now)

US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(5 months from now)

CN101633644B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN100519539C ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682A ARRAY BIOPHARMA INC N3 Alkylated Benzoimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN1652776A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

CN101633644A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

IN200403046P1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

IN248684B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2130537B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130536B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2130536A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130537A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A4 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal Mar, 2023

(5 months from now)

US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors Mar, 2023

(5 months from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Method of treating melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription

88. Drug name - MOZOBIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7897590 GENZYME Methods to mobilize progenitor/stem cells Jul, 2023

(9 months from now)

US6987102 GENZYME Methods to mobilize progenitor/stem cells Jul, 2023

(9 months from now)

Drugs and Companies using PLERIXAFOR ingredient

Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
24MG/1.2ML (20MG/ML) SOLUTION;SUBCUTANEOUS Prescription

89. Drug name - MYDAYIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts May, 2023

(7 months from now)

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

90. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 29 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049 APGDI α-form or β-form crystal of acetanilide derivative Nov, 2023

(1 year, 29 days from now)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Nov, 2023

(1 year, 29 days from now)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Nov, 2023

(1 year, 29 days from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

91. Drug name - MYRBETRIQ GRANULES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 29 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049 APGDI α-form or β-form crystal of acetanilide derivative Nov, 2023

(1 year, 29 days from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

92. Drug name - NAROPIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids May, 2023

(7 months from now)

More Information on Dosage
Strength Dosage Availability
1GM/200ML (5MG/ML) SOLUTION;INJECTION Prescription
50MG/10ML (5MG/ML) SOLUTION;INJECTION Discontinued
20MG/10ML (2MG/ML) SOLUTION;INJECTION Prescription
40MG/20ML (2MG/ML) SOLUTION;INJECTION Prescription
75MG/10ML (7.5MG/ML) SOLUTION;INJECTION Discontinued
100MG/20ML (5MG/ML) SOLUTION;INJECTION Prescription
100MG/10ML (10MG/ML) SOLUTION;INJECTION Prescription
150MG/20ML (7.5MG/ML) SOLUTION;INJECTION Prescription
150MG/30ML (5MG/ML) SOLUTION;INJECTION Prescription
200MG/100ML (2MG/ML) SOLUTION;INJECTION Prescription
200MG/20ML (10MG/ML) SOLUTION;INJECTION Prescription
400MG/200ML (2MG/ML) SOLUTION;INJECTION Prescription
500MG/100ML (5MG/ML) SOLUTION;INJECTION Prescription

93. Drug name - NATROBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6063771 PARAPRO LLC Formulations for controlling human lice Jul, 2023

(9 months from now)

Drugs and Companies using SPINOSAD ingredient

Treatment: Natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older.

Dosage: SUSPENSION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.9% SUSPENSION;TOPICAL Prescription

94. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591 UCB INC Transdermal delivery system for the administration of rotigotine Jul, 2023

(9 months from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

95. Drug name - NEXAVAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity Feb, 2023

(4 months from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Treatment: Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

96. Drug name - NEXLETOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using BEMPEDOIC ACID ingredient

Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexletol as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
180MG TABLET;ORAL Prescription

97. Drug name - NEXLIZET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
180MG;10MG TABLET;ORAL Prescription

98. Drug name - NOCDURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919025 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(6 months from now)

US9220747 FERRING PHARMS INC Methods using desmopressin acetate in orodispersible form May, 2023

(6 months from now)

US9504647 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(6 months from now)

US10307459 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(6 months from now)

US8802624 FERRING PHARMS INC Methods of treatment using orodispersible desmopressin pharmaceutical formulations Dec, 2023

(1 year, 2 months from now)

US7947654 FERRING PHARMS INC Pharmaceutical formulations Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.0277MG TABLET;SUBLINGUAL Prescription
0.0553MG TABLET;SUBLINGUAL Prescription

99. Drug name - NOCTIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7405203 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin May, 2023

(6 months from now)

US7579321 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin May, 2023

(6 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: A method of treating nocturia due to nocturnal polyuria in adults

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.00083MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.00166MG/SPRAY SPRAY, METERED;NASAL Discontinued

100. Drug name - NORMOCARB HF 25

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7300674 DIALYSIS SUPS Sterile low bicarbonate dialysis concentrate solutions Mar, 2023

(4 months from now)

Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient

Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy

Dosage: SOLUTION;INJECTION

More Information on Dosage
Strength Dosage Availability
0.21GM/100ML;2.8GM/100ML;9.07GM/100ML SOLUTION;INJECTION Prescription
0.21GM/100ML;3.97GM/100ML;8.3GM/100ML SOLUTION;INJECTION Prescription

101. Drug name - NOURIANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders Jan, 2023

(3 months from now)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy Jan, 2023

(3 months from now)

Drugs and Companies using ISTRADEFYLLINE ingredient

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

102. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: Relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

103. Drug name - NUEDEXTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227484 AVANIR PHARMS Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Jul, 2023

(9 months from now)

Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient

Treatment: Treatment of pseudobulbar affect

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;10MG CAPSULE;ORAL Prescription

104. Drug name - NUVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(1 year, 2 months from now)

IN200501304P4 CEPHALON Process For The Preperation Of And
Dec, 2023

(1 year, 2 months from now)

IN256037B CEPHALON A Process For The Preperation Of Crystalline Forms Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP1572635A1 CEPHALON Method For The Production Of Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275A3 CEPHALON Process For The Preparation And Crystalline Form I Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578A3 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275B1 CEPHALON Crystalline Form Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578A2 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP1572635B1 CEPHALON Method For The Production Of Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275A2 CEPHALON Crystalline Form Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578B1 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Discontinued
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription
250MG TABLET;ORAL Prescription

105. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2023

(7 months from now)

US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(11 months from now)

IN200402212P4 PARATEK PHARMS INC Amino-Methyl Substituted Tetracycline Compounds
Mar, 2023

(5 months from now)

IN228816B PARATEK PHARMS INC Amino-Methyl Substituted Tetracycline Compound
Mar, 2023

(5 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

106. Drug name - NYMALIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581 ARBOR PHARMS LLC Dispenser for medicaments and method and apparatus for making same Jun, 2023

(8 months from now)

Drugs and Companies using NIMODIPINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
3MG/ML SOLUTION;ORAL Discontinued
6MG/ML SOLUTION;ORAL Prescription

107. Drug name - ODEFSEY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

108. Drug name - OMIDRIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399040 RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jul, 2023

(9 months from now)

US8173707 RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jul, 2023

(9 months from now)

US9278101 RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jul, 2023

(9 months from now)

US8586633 RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jul, 2023

(9 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: Maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain

Dosage: SOLUTION;IRRIGATION

More Information on Dosage
Strength Dosage Availability
EQ 0.3% BASE;EQ 1% BASE SOLUTION;IRRIGATION Prescription

109. Drug name - ONGLYZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription

110. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 29 days from now)

US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 29 days from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

111. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices Jul, 2023

(8 months from now)

US8327844 CURRAX Nasal delivery method Oct, 2023

(11 months from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

112. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309112 ENDO PHARMS Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same Feb, 2023

(3 months from now)

US7276250 ENDO PHARMS Sustained release formulations of oxymorphone Feb, 2023

(3 months from now)

US8329216 ENDO PHARMS Oxymorphone controlled release formulations Feb, 2023

(3 months from now)

US8309122 ENDO PHARMS Oxymorphone controlled release formulations Feb, 2023

(3 months from now)

US8075872 ENDO PHARMS Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 ENDO PHARMS Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: Relief of moderate to severe pain

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

113. Drug name - ORAVERSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229630 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof Jun, 2023

(8 months from now)

US7569230 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof Oct, 2023

(1 year, 11 days from now)

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
0.4MG/1.7ML INJECTABLE;INJECTION Prescription

114. Drug name - OTEZLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(1 year, 2 months from now)

CN1965823B AMGEN INC (+) -2-[3 - (1-Ethoxy - -4 - Methoxyphenyl) -2 - Methylsulfonyl-Ethyl] -4 - Stereomeric - -1, 3-Diketone, Its Synthetic Method And Its Composition
Mar, 2023

(5 months from now)

CN1652772A AMGEN INC (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Diketone Using The Method And Composition Thereof
Mar, 2023

(5 months from now)

CN1965823A AMGEN INC (+)-2-(1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl)-4-Acetylamino Isoindoline-1,3-Dione, Synthesis Method And Composition Thereof
Mar, 2023

(5 months from now)

CN100427085C AMGEN INC (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Pharmaceutical Use Of Diketone
Mar, 2023

(5 months from now)

EP2295055A3 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2295055A2 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2311453A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2295055B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2311453B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP1485087B1 AMGEN INC (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration
Mar, 2023

(5 months from now)

EP2420490B1 AMGEN INC Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
Mar, 2023

(5 months from now)

EP2420490A1 AMGEN INC Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
Mar, 2023

(5 months from now)

EP1485087A1 AMGEN INC (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration
Mar, 2023

(5 months from now)

EP2962690A1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

EP2962690B1 AMGEN INC (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Mar, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof Mar, 2023

(5 months from now)

US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione Mar, 2023

(5 months from now)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof Mar, 2023

(5 months from now)

US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione Mar, 2023

(5 months from now)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione Mar, 2023

(5 months from now)

Drugs and Companies using APREMILAST ingredient

Treatment: Use of otezla (apremilast) for the treatment of psoriatic arthritis; Use of otezla (apremilast) for inhibiting pde4; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with active psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

115. Drug name - OXAYDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981439 ZYLA Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof Nov, 2023

(1 year, 1 month from now)

US8637540 ZYLA Compositions for deterring abuse of opioid containing dosage forms Nov, 2023

(1 year, 1 month from now)

US8409616 ZYLA Extended release opioid abuse deterrent compositions and methods of making same Nov, 2023

(1 year, 1 month from now)

US7510726 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription

116. Drug name - OXYCONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10369109 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms Nov, 2023

(1 year, 1 month from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, EXTENDED RELEASE;ORAL Prescription
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription

117. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

118. Drug name - OZURDEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034366 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US8034370 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US10076526 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US9192511 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US10702539 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US8506987 ALLERGAN Ocular implant made by a double extrusion process Jan, 2023

(3 months from now)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants Nov, 2023

(1 year, 26 days from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Treatment of macular edema; treatment of uveitis; Treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage
Strength Dosage Availability
0.7MG IMPLANT;INTRAVITREAL Prescription

119. Drug name - PATANASE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977376 NOVARTIS Olopatadine formulations for topical nasal administration Feb, 2023

(3 months from now)

US8399508

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration Mar, 2023

(5 months from now)

US7977376

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration Aug, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
0.665MG/SPRAY SPRAY, METERED;NASAL Prescription

120. Drug name - PHEXXI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6706276 EVOFEM INC Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Mar, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
1%;1.8%;0.4% GEL;VAGINAL Prescription

121. Drug name - POMALYST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione May, 2023

(7 months from now)

US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione May, 2023

(7 months from now)

US8673939

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Nov, 2023

(1 year, 1 month from now)

US8735428

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using POMALIDOMIDE ingredient

Treatment: Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG CAPSULE;ORAL Prescription
2MG CAPSULE;ORAL Prescription
3MG CAPSULE;ORAL Prescription
4MG CAPSULE;ORAL Prescription

122. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Jun, 2023

(8 months from now)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Dec, 2023

(1 year, 2 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/PACKET PELLETS;ORAL Prescription
EQ 30MG BASE/PACKET PELLETS;ORAL Prescription
EQ 40MG BASE/PACKET PELLETS;ORAL Prescription
EQ 50MG BASE/PACKET PELLETS;ORAL Prescription
EQ 110MG BASE/PACKET PELLETS;ORAL Prescription
EQ 150MG BASE/PACKET PELLETS;ORAL Prescription

123. Drug name - PRESTALIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6696481 ADHERA Salt of perindopril and pharmaceutical compositions containing it
Apr, 2023

(6 months from now)

CN1211365C ADHERA Perindopril Of New Salt And Pharmaceutical Composition Containing The Same
Feb, 2023

(4 months from now)

CN1451656A ADHERA Perindopril Of New Salt And Pharmaceutical Composition Containing The Same
Feb, 2023

(4 months from now)

IN235613B ADHERA New Salt Of Perindopril And Pharmaceutical Compositions Containing It
Feb, 2023

(4 months from now)

EP1354873A1 ADHERA Salt Of Perindopril And Pharmaceutical Compositions Containing It
Feb, 2023

(4 months from now)

EP1354873B1 ADHERA Salt Of Perindopril And Pharmaceutical Compositions Containing It
Feb, 2023

(4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE;3.5MG TABLET;ORAL Prescription
EQ 5MG BASE;7MG TABLET;ORAL Prescription
EQ 10MG BASE;14MG TABLET;ORAL Prescription

124. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler May, 2023

(6 months from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

125. Drug name - PROAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7105152 TEVA BRANDED PHARM Suspension aerosol formulations Sep, 2023

(11 months from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

126. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics May, 2023

(7 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May, 2023

(7 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of idiopathic thrombocytopenic purpura (itp)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID TABLET;ORAL Prescription
EQ 25MG ACID TABLET;ORAL Prescription
EQ 50MG ACID TABLET;ORAL Prescription
EQ 75MG ACID TABLET;ORAL Prescription
EQ 100MG ACID TABLET;ORAL Discontinued

127. Drug name - PROMACTA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics May, 2023

(7 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May, 2023

(7 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID/PACKET FOR SUSPENSION;ORAL Prescription
EQ 25MG ACID/PACKET FOR SUSPENSION;ORAL Prescription

128. Drug name - PROVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil Nov, 2023

(1 year, 1 month from now)

Drugs and Companies using MODAFINIL ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

129. Drug name - QTERN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
5MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 5MG BASE TABLET;ORAL Prescription

130. Drug name - QTERNMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

131. Drug name - QUTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869827 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces Sep, 2023

(10 months from now)

US8889113 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces Sep, 2023

(10 months from now)

US10463598 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces Sep, 2023

(10 months from now)

US8263059 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces Sep, 2023

(10 months from now)

Drugs and Companies using CAPSAICIN ingredient

Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area

Dosage: PATCH;TOPICAL

More Information on Dosage
Strength Dosage Availability
8% PATCH;TOPICAL Prescription

132. Drug name - RAPIVAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using PERAMIVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

133. Drug name - REBETOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6790837 SCHERING Ribavirin syrup formulations Apr, 2023

(5 months from now)

US6790837

(Pediatric)

SCHERING Ribavirin syrup formulations Oct, 2023

(11 months from now)

Drugs and Companies using RIBAVIRIN ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML SOLUTION;ORAL Discontinued

134. Drug name - RECLAST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates Oct, 2023

(1 year, 21 days from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

135. Drug name - REVLIMID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7189740 CELGENE Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes Apr, 2023

(6 months from now)

US8404717 CELGENE Methods of treating myelodysplastic syndromes using lenalidomide Apr, 2023

(6 months from now)

US9056120 CELGENE Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine Apr, 2023

(6 months from now)

US9393238 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent May, 2023

(7 months from now)

US8648095 CELGENE Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor May, 2023

(7 months from now)

US9101621 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation May, 2023

(7 months from now)

US8530498 CELGENE Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione May, 2023

(7 months from now)

US9101622 CELGENE Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone May, 2023

(7 months from now)

US9155730 CELGENE Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent May, 2023

(7 months from now)

US7968569 CELGENE Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 1 day from now)

US7468363 CELGENE Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 1 day from now)

US8492406 CELGENE Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione Oct, 2023

(1 year, 1 day from now)

Drugs and Companies using LENALIDOMIDE ingredient

Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; Use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct); Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma; Use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG CAPSULE;ORAL Prescription
5MG CAPSULE;ORAL Prescription
10MG CAPSULE;ORAL Prescription
15MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

136. Drug name - REYVOW

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists Mar, 2023

(5 months from now)

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Discontinued

137. Drug name - RUBRACA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6495541 CLOVIS ONCOLOGY INC Tricyclic inhibitors of poly(ADP-ribose) polymerases
Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 250MG BASE TABLET;ORAL Prescription
EQ 300MG BASE TABLET;ORAL Prescription

138. Drug name - RYANODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685460 EAGLE PHARMS Treatment using dantrolene Feb, 2023

(4 months from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL FOR SUSPENSION;INTRAVENOUS Prescription

139. Drug name - RYZOLT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7988998 PURDUE PHARMA Sustained-release tramadol formulations with 24-hour efficacy Oct, 2023

(1 year, 21 days from now)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET, EXTENDED RELEASE;ORAL Discontinued
200MG TABLET, EXTENDED RELEASE;ORAL Discontinued
300MG TABLET, EXTENDED RELEASE;ORAL Discontinued

140. Drug name - SAVELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6602911 ALLERGAN Methods of treating fibromyalgia Jan, 2023

(3 months from now)

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

Treatment: Management of fibromyalgia (fm)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
12.5MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

141. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs Feb, 2023

(4 months from now)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

142. Drug name - SEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG,0.01MG;0.15MG,N/A TABLET;ORAL Prescription

143. Drug name - SELZENTRY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy May, 2023

(7 months from now)

Drugs and Companies using MARAVIROC ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/ML SOLUTION;ORAL Prescription

144. Drug name - SIGNIFOR LAR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues Aug, 2023

(9 months from now)

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage